middle.news
Neurotech Launches Phase 3 Trial Site for Autism Treatment NTI164
9:44am on Tuesday 17th of March, 2026 AEDT
•
Healthcare
Read Story
Neurotech Launches Phase 3 Trial Site for Autism Treatment NTI164
9:44am on Tuesday 17th of March, 2026 AEDT
Key Points
First Phase 3 clinical site activated at Monash Children’s Hospital
Multi-centre, randomised, placebo-controlled trial design
Evaluating NTI164’s efficacy and safety in paediatric Autism Spectrum Disorder
Planned enrolment of 150 patients with adaptive trial design
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
NEUROTECH INTERNATIONAL (ASX:NTI)
OPEN ARTICLE